Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA
Oramed Pharmaceuticals Inc. (ORMP)
Last oramed pharmaceuticals inc. earnings: 4/6 04:46 pm
Check Earnings Report
US:NASDAQ Investor Relations:
oramed.com/investors
Company Research
Source: PR Newswire
NEW YORK, March 19, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive feedback from its initial End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss Chemistry Manufacturing and Control (CMC) of its lead oral insulin capsule ORMD-0801. The meeting, held in February, followed the successful completion of Oramed's Phase 2b trial of ORMD-0801 for the treatment of type 2 diabetes (See Press Release dated November 12, 2019), which achieved its primary endpoint, the reduction in HbA1c compared to placebo at week 12. During this meeting the FDA provided feedback on key issues relating to Drug Product manufacture and supported continuing to Phase 3 clinical development. The Company expects an additional meeting with the FDA following deeper analysis of the data from the Phase 2b trial, durin
Show less
Read more
Impact Snapshot
Event Time:
ORMP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORMP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORMP alerts
High impacting Oramed Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ORMP
News
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
ORMP
Earnings
- 8/14/24 - Beat
ORMP
Sec Filings
- 12/17/24 - Form 8-K
- 11/8/24 - Form 4
- 11/8/24 - Form 4
- ORMP's page on the SEC website